Unigene Laboratories, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Unigene Laboratories, Inc.
Saying its review found “no conclusive evidence of a causal relationship” between the products and cancer, agency is allowing continued marketing of Miacalcin and Fortical nasal sprays but limiting use to only those post-menopausal women for whom alternative treatments are not suitable.
A new life sciences hedge fund operated by two former associates of activist investor Carl Icahn is challenging Otsuka’s takeover of cancer drug developer Astex. Also, Johnson & Johnson’s London Innovation Center announced four alliances, Celgene took another option on one of its investments and Takeda teamed up with New York research institutions to form a new discovery institute.
Newly formed Enteris inks its first licensing deal as it tries to prove to potential partners that its technology can help company up-cycle old drugs and improve their patent life by making them orally available.
New bone-targeted agents for osteoporosis must clear significant obstacles to succeed in a highly generic market, but safety concerns with established agents like bisphosphonates and calcitonin offer a foothold. Phase III anabolic candidates from Amgen and Radius Health aim to build new bone, the holy grail of osteoporosis treatment, but R&D in new anti-resorptive mechanisms to halt bone breakdown also continues.
- Large Molecule
Drug Discovery Tools
- Natural Products
- Molecular Diversity